FDA Approves First Targeted Therapy to Treat Aggressive Form of Lung Cancer

U.S. Food and Drug Administration approved Tabrecta (capmatinib) for the treatment of adult patients with non-small cell lung cancer (NSCLC) that has spread to other parts of the body. Tabrecta is the first FDA-approved therapy to treat NSCLC with specific mutations (those that lead to mesenchymal-epithelial transition or MET exon 14 skipping).

source https://www.pharmatutor.org/pharma-news/2020/fda-approves-first-targeted-therapy-to-treat-aggressive-form-of-lung-cancer